Thermo Fisher Scientific reported second-quarter 2026 results with revenue of $11.99B, net income of $1.74B and diluted EPS of $4.68, all up versus the prior-year quarter as the company cited strength across pharma/biotech, high-end instruments and efficiency gains.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$11.99B$10.86B10.5% | Net income²$1.74B$1.62B7.4% | Diluted EPS³$4.68$4.289.3% |
¹ Reported as “Total revenues”. ² Reported as “Net income attributable to Thermo Fisher Scientific Inc.”. ³ Reported as “Diluted earnings per share attributable to Thermo Fisher Scientific Inc.”.
Business Highlights
- Revenue growth was broad-based, driven by pharma/biotech demand and sales of high-end instruments.
- Strength across channels and regions, with momentum in Europe and Asia‑Pacific and gains in pharma, industrial, academic and diagnostics customers.
- Lab Products & Biopharma Services and Analytical Instruments were key organic contributors, aided by clinical research demand and electron microscopy.
- Completed acquisitions including Clario and filtration/separation assets to expand bioproduction and clinical research capabilities.
- Operational productivity initiatives (PPI) delivered margin expansion despite unfavorable mix and ongoing strategic investments.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.